2024 • Volume • • Electronic publication date: 28/03/2024

COVID-19 Australia: Epidemiology Report 81 Reporting period ending 19 November 2023

Viral Respiratory Diseases Epidemiology and Surveillance Section

# Summary

Four-week reporting period (23 October – 19 November 2023)

Case definitions for confirmed and probable cases are in accordance with the coronavirus disease 2019 (COVID-19) CDNA National Guidelines for Public Health Units.

Trends – Nationally, case notifications have slowly increased from late August to early September 2023, and have stabilised in recent weeks. In the four-week period 23 October – 19 November 2023, there were 26,871 confirmed and 11,612 probable cases, a total of 38,483 COVID-19 cases reported in Australia to the National Notifiable Diseases Surveillance System (NNDSS). In the most recent reporting fortnight, a total of 20,598 confirmed and probable cases were notified (an average of 1,471 cases per day), compared to 17,885 in the previous fortnight (an average of 1,278 cases per day), representing a 15% increase.

Age group – Overall, notification rates among most age groups have stabilised following the end of the fifth Omicron wave in mid-August 2023. In the current reporting period, 23 October – 19 November 2023, the highest notification rate was observed among adults aged 90 years and over, whilst the lowest rates were among young people aged 10–19 years.

Aboriginal and Torres Strait Islander people – In the reporting period 23 October – 19 November 2023, there were 1,014 new cases notified in Aboriginal and Torres Strait Islander people, accounting for 2.6% of all cases (1,014/38,483) during this time. In the Omicron wave to date (15 December 2021 – 19 November 2023), there have been 433,658 cases notified among Aboriginal and Torres Strait Islander people, representing 3.8% of all cases (433,658/11,443,294) during this period.

Severity – Since the emergence of the Omicron variant, there has been a consistent decrease in the incidence of severe illness, with a smaller peak observed with each subsequent Omicron wave. This may be due to the lessening societal impact of the pandemic due to high COVID-19 vaccination coverage, hybrid immunity and access to oral antiviral treatments. Compared with previous Omicron waves, the number of cases with severe illness remained low and stable between mid to late August 2023, followed by a gradual increase from early September, signalling the start of the sixth Omicron wave. The overall crude case fatality rate from the start of the Omicron wave to date is 0.19%, which is lower than the crude rate during the Delta wave (0.71%).

Virology – For samples collected in the four-week period 23 October – 19 November 2023, all sequences uploaded to AusTrakka were assigned against Omicron or recombinants consisting of Omicron lineages. This represents a 35% increase in the number of sequences compared to the previous reporting period. In this reporting period, of the 1,109 sequences uploaded to AusTrakka during 23 October – 19 November 2023, most (90.8%) were recombinant or recombinant sub-lineages; and 9.2% were BA.2 sub-sub lineages.

Acute respiratory illness – Based on self-reported FluTracking data, there has been an overall decrease in the incidence of respiratory illness, ‘fever and cough’ and ‘runny nose and sore throat’ symptoms since the peak in early June 2023. Over the current period, the weekly average proportion of ‘fever and cough’ (1.4%) and ‘runny nose and sore throat’ (1.3%) were similar to proportions observed during the same period in 2022.

International situation – According to the World Health Organization (WHO), as of 22 October 2023, over 772 million COVID-19 cases and over six million deaths have been reported globally since the start of the pandemic, with a global case fatality rate (CFR) of approximately 0.90%.

Keywords: SARS-CoV-2; novel coronavirus; coronavirus disease 2019; COVID-19; acute respiratory disease; epidemiology; Australia

This reporting period covers the four-week period 23 October – 19 November 2023. Within this period, data for each week is compared. The previous reporting period was the preceding four weeks (25 September – 22 October 2023).1 The focus of this report is on the epidemiological situation in Australia since the beginning of the Omicron wave. For the purposes of this report, 15 December 2021 is used as a proxy for the beginning of this wave. This date was chosen as from this date onward, most sequenced strains from cases were Omicron. Readers are encouraged to consult prior reports in this series for information on the epidemiology of coronavirus disease 2019 (COVID-19) in Australia.

Methods of data analysis in these reports have periodically changed over the course of this reporting series to date. Please refer to the Technical Supplement for details of such changes, and for definitions of terminology.2

From Report #72 onward, and unless specified otherwise, all data from the National Notifiable Diseases Surveillance System (NNDSS) have been extracted using ‘diagnosis date’ rather than ‘notification received date’ (see the Technical Supplement for definitions). Due to COVID-19 reporting changes in several states and territories, the use of ‘diagnosis date’ now provides a more consistent and accurate method for describing transmission trends in Australia.

The case data provided includes both confirmed cases and probable cases reported to the NNDSS, as defined in accordance with the COVID-19 Communicable Diseases Network Australia (CDNA) National Guidelines for Public Health Units.3 For the purposes of this report, only probable cases from 5 January 2022 are included. Five jurisdictions have ceased collecting and reporting data on probable COVID-19 cases: Victoria ceased collection on 1 July 2023, Queensland on 1 September 2023, New South Wales on 1 October 2023, Western Australia on 9 October 2023, and the Northern Territory on 21 October 2023.

From Report #71 onward, population data for Aboriginal and Torres Strait Islander people was updated (from 2016) and is now based on Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) as at 2021. There has been an increase of 185,600 Aboriginal and Torres Strait Islander people (23.2%) since the previous ERP (June 2016). Therefore, notification rate comparisons with reports prior to #71 should be undertaken with caution.

Due to the dynamic nature of data in the NNDSS, numbers may be subject to revision and may vary from numbers previously reported and from case notifications released by states and territories.

# Background and data sources

See the Technical Supplement for general information on COVID-19 including modes of transmission, common symptoms, and severity.2


# Activity

## COVID-19 trends

(NNDSS)

Since the beginning of the pandemic to 19 November 2023, jurisdictions in Australia have reported 11,686,730 COVID-19 cases to the NNDSS. Nationally, case notifications have slowly increased from late August to early September 2023, and have stabilised in recent weeks (Figure 1).

Figure 1: Confirmed and probable weekly COVID-19 notified cases by date of onset, Australia, 26 December 2022 – 19 November 2023a,b



a Source: NNDSS, extracted on 22 November 2023 for cases with an illness onset from 26 December 2022 to 19 November 2023.

b Since 1 July 2023, several jurisdictions have progressively ceased collecting and reporting data on probable COVID-19 cases.

In the four-week period 23 October – 19 November 2023, there were 26,871 confirmed and 11,612 probable cases of COVID-19 reported in Australia to the NNDSS (Table 1). In the most recent reporting fortnight, a total of 20,598 confirmed and probable cases were notified (an average of 1,471 cases per day), compared to 17,885 in the previous fortnight (an average of 1,278 cases per day), representing a 15% increase.

Table 1: **Confirmed and probable COVID-19 cases by jurisdiction and date of illness onset, Australia,   
15 December 2021 – 19 November 2023** a,b,c

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Reporting period | | | | | | Omicron wave to date | | |
|  | 23 October – 5 November 2023 | | | 6–19 November 2023 | | | 15 December 2021 –  19 November 2023 | | |
| **Jurisdiction** | Confirmed | Probable | Total | Confirmed | Probable | Total | Confirmed | Probable | Total |
| ACT | 231 (23.1%) | 771 (76.9%) | 1,002 | 216  (19.9%) | 869 (80.1%) | 1,085 | 133,739 (54.0%) | 113,865 (46.0%) | 247,604 |
| NSW**d** | 4,728 (94.8%) | 260 (5.2%) | 4,988 | 5,353 (93.2%) | 390 (6.8%) | 5,743 | 2,168,231 (56.3%) | 1,683,600 (43.7%) | 3,851,831 |
| NT**d** | 217 (100.0%) | 0 (0.0%) | 217 | 273 (100.0%) | 0 (0.0%) | 273 | 25,514 (23.3%) | 84,177 (76.7%) | 109,691 |
| Qld**d** | 2,164 (91.1%) | 212  (8.9%) | 2,376 | 2,927 (94.3%) | 178  (5.7%) | 3,105 | 704,988 (40.4%) | 1,039,891 (59.6%) | 1,744,879 |
| SA | 1,236 (31.9%) | 2,642 (68.1%) | 3,878 | 1,233 (26.4%) | 3,436 (73.6%) | 4,669 | 533,940 (56.2%) | 416,624 (43.8%) | 950,564 |
| Tas. | 224  (15.3%) | 1,242 (84.7%) | 1,466 | 242  (13.2%) | 1,598 (86.8%) | 1,840 | 67,683 (21.9%) | 242,053 (78.1%) | 309,736 |
| Vic.**d** | 3,032 (99.6%) | 12 (0.4%) | 3,044 | 2,872 (100.0%) | 1 (0.0%) | 2,873 | 1,110,698 (39.0%) | 1,737,673 (61.0%) | 2,848,371 |
| WA**d** | 913  (99.9%) | 1 (0.1%) | 914 | 1,010 (100.0%) | 0 (0.0%) | 1,010 | 505,779 (36.6%) | 874,839 (63.4%) | 1,380,618 |
| Australia | 12,745 (71.3%) | 5,140 (28.7%) | 17,885 | 14,126 (68.6%) | 6,472 (31.4%) | 20,598 | 5,250,572 (45.9%) | 6,192,722 (54.1%) | 11,443,294 |

a Source: NNDSS, extracted on 22 November 2023 for cases with an illness onset from 15 December 2021 to 19 November 2023.

b ACT: Australian Capital Territory; NSW: New South Wales; NT: Northern Territory; Qld: Queensland; SA: South Australia; Tas.: Tasmania; Vic.: Victoria; WA: Western Australia.

c Since 1 July 2023, cases are classified based on jurisdiction of residence. This does not necessarily reflect the place where the disease was acquired or where the case presented. Please note prior to this, cases were classified based on the jurisdiction in which they tested positive.

d Five jurisdictions ceased collecting and reporting data on probable COVID-19 cases: Victoria ceased collection on 1 July 2023, Queensland on 1 September 2023, New South Wales on 1 October 2023, Western Australia on 9 October 2023, and the Northern Territory on 21 October 2023. Rapid antigen tests (probable COVID-19 cases) administered in healthcare or aged care settings continue to be reported to the NNDSS by some of these jurisdictions.

As the pandemic has progressed, the proportion of cases reported through traditional surveillance has decreased and there are many different sub-lineages of virus circulating simultaneously. Additionally, increases in other measures of disease activity, such as the numbers of people admitted to hospital, to intensive care units (ICU), or having died, often lag weeks behind increases in infections in the community. This has made defining the start of a new wave more complex, with the determination often now only possible several weeks after the wave has commenced.


Since the emergence of the Omicron variant in Australia, there have been six distinct waves of transmission, defined by the predominant Omicron subvariant circulating. The first wave, of the BA.1 subvariant, occurred from mid-December 2021 to February 2022, with a peak in cases observed in early January 2022. From March 2022, the BA.2 subvariant was the predominant strain; in this second Omicron wave, there was a primary peak in early April and a secondary peak in late May 2022. In early July 2022, BA.5 (including sub-lineages) became the predominant subvariant detected in Australia, driving a third wave of transmission which peaked in the week ending 24 July 2022. A fourth wave of transmission commenced in late October 2022, driven by a combination of existing and newly emerging Omicron subvariants. This wave peaked during the week ending 11 December 2022. A fifth Omicron wave of transmission, similarly driven by a combination of existing and newly emerging recombinant Omicron subvariants, led to a peak in notifications in the week ending 21 May 2023 (Figure 1). The most recent sixth wave of transmission commenced in late August 2023, signalled by an increasing trend in several surveillance indicators (Figures 1, 3 and 5).

## Demographic features

(NNDSS)

Following the end of the fifth Omicron wave in mid-August 2023, notification rates among most age groups have remained low and stable, except among adults aged 60 years and over where rates have slowly increased and remain the highest rates among all age groups (Figure 2). In the current reporting period, 23 October – 19 November 2023, the highest notification rate was observed among adults aged 90 years and over, whilst the lowest rate was among young people aged 10–19 years (Appendix A, Table A.1).

Figure 2: **Confirmed and probable COVID-19 notification weekly rates for ten-year age groups by date of onset, Australia, 26 December 2022 – 19 November 2023** a,b



a Source: NNDSS, extracted on 22 November 2023 for cases with an illness onset from 26 December 2022 to 19 November 2023.

b Population data based on Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) as at June 2022.

### Aboriginal and Torres Strait Islander persons

(NNDSS)

Overall, since the start of the pandemic, Aboriginal and Torres Strait Islander status is unknown for approximately 13.2% of COVID-19 notifications in NNDSS. Therefore, the number of cases classified as Aboriginal and Torres Strait Islander people is likely an under-representation. During the reporting period, there were 1,014 new cases notified among Aboriginal and Torres Strait Islander people (Table 2). In the Omicron wave to date (15 December 2021 – 19 November 2023), notifications among Aboriginal and Torres Strait Islander people have comprised 3.8% of all cases (433,658/11,443,294).

Table 2: **Confirmed and probable cases of COVID-19 among Aboriginal and Torres Strait Islander peoples by jurisdiction and date of onset, Australia, 1 January 2020 – 19 November 2023** a,b,c

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Jurisdiction b,c | Reporting period 23 October –  19 November 2023 | Omicron wave to date 15 December 2021 –  19 November 2023 | Delta wave 16 June – 14 December 2021 | Pandemic to date 1 January 2020 –  19 November 2023 |
| ACT | 19 | 4,310 | 240 | 4,554 |
| NSW | 233 | 139,472 | 7,719 | 147,262 |
| NT | 168 | 26,858 | 94 | 26,953 |
| Qld | 275 | 113,089 | 19 | 113,131 |
| SA | 73 | 24,164 | 3 | 24,172 |
| Tas. | 133 | 17,522 | 1 | 17,535 |
| Vic. | 28 | 36,417 | 1,938 | 38,451 |
| WA | 85 | 61,598 | 0 | 61,600 |
| Australia | 1,014 | 423,430 | 10,014 | 433,658 |

a Source: NNDSS, extracted on 22 November 2023 for cases with an illness onset from 1 January 2020 to 19 November 2023.

b ACT: Australian Capital Territory; NSW: New South Wales; NT: Northern Territory; Qld: Queensland; SA: South Australia; Tas: Tasmania; Vic: Victoria; WA: Western Australia.

c Since 1 July 2023, cases are classified based on jurisdiction of residence. This does not necessarily reflect the place where the disease was acquired or where the case presented. Please note that, prior to this, cases were classified based on the jurisdiction in which they tested positive.

Of the COVID-19 cases notified among Aboriginal and Torres Strait Islander people from 15 December 2021 to date, and where location of residence was known, 54.9% (230,981/420,570) lived in a regional or remote area (Table 3).

Nationally, there have been 435 COVID-19 associated deaths reported in Aboriginal and Torres Strait Islander people from the start of the pandemic to 19 November 2023. This comprises 143 (32.9%) from New South Wales; 129 (29.7%) from Queensland; 59 (13.6%) from Western Australia; 58 (13.3%) from the Northern Territory; 25 (5.8%) from South Australia; 17 (3.9%) from Victoria; and two (0.5%) each from the Australian Capital Territory and Tasmania. Additionally, 762 Aboriginal and Torres Strait Islander cases have been admitted to ICUs nationally. The overall population rate of severe illness (measured as those who were admitted to ICU or died) in Aboriginal and Torres Strait Islander people during the fifth Omicron wave (12.3 per 100,000 population) was lower than the rate observed during the fourth Omicron wave (14.8 per 100,000 population; Table 4). In the Omicron wave to date, the population rate of severe illness increased with age, with the highest rate observed among those aged 60 years and over (Table 4). It should be noted that ICU status in NNDSS is likely incomplete.

Table 3: **COVID-19 cases among Aboriginal and Torres Strait Islander people by area of remoteness, Australia, 15 December 2021 – 19 November 2023** a

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Jurisdiction b,c | Major city | Inner regional | Outer regional | Remote d |
| ACT | 4,261 | 35 | 12 | 1 |
| NSW | 74,833 | 45,118 | 15,573 | 3,166 |
| NT | 74 | 21 | 8,430 | 17,416 |
| Qld | 44,137 | 26,061 | 31,258 | 11,479 |
| SA | 13,102 | 2,600 | 5,045 | 3,259 |
| Tas. | 206 | 10,729 | 6,140 | 299 |
| Vic. | 20,755 | 11,741 | 3,862 | 19 |
| WA | 32,221 | 4,458 | 7,703 | 16,556 |
| Australia | 189,589 | 100,763 | 78,023 | 52,195 |

a Source: NNDSS, extracted on 22 November 2023 for cases with an illness onset from 15 December 2021 to 19 November 2023. Excludes cases with an overseas place of residence, and where place of residence is unknown.

b ACT: Australian Capital Territory; NSW: New South Wales; NT: Northern Territory; Qld: Queensland; SA: South Australia; Tas.: Tasmania; Vic.: Victoria; WA: Western Australia.

c Since 1 July 2023, cases are classified based on jurisdiction of residence. This does not necessarily reflect the place where the disease was acquired or where the case presented. Please note that, prior to this, cases were classified based on the jurisdiction in which they tested positive.

d ‘Remote’ here also includes areas classified as ‘very remote’.

Table 4: **Age-specific rates of COVID-19 cases by highest level of illness severity (admitted to ICU and/or died) in Aboriginal and Torres Strait Islander people, Australia, 1 January 2020 to 19 November 2023** a

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Age group (years) | Sixth Omicron wave to date 14 August –  19 November 2023 | Fifth Omicron wave 1 March – 13 August 2023 | Fourth Omicron wave 24 October 2022 –  28 February 2023 | Omicron wave to date 15 December 2021 – 19 November 2023 | Pandemic to date 1 January 2020 – 19 November 2023 |
| 0–9 | 0.5 | 0.9 | 5.1 | 22.3 | 23.3 |
| 10–19 | 0.5 | 3.4 | 1.9 | 21.3 | 26.1 |
| 20–29 | 0.6 | 3.0 | 3.0 | 44.2 | 53.2 |
| 30–39 | 0.0 | 3.2 | 11.3 | 53.2 | 68.5 |
| 40–49 | 4.0 | 7.1 | 10.1 | 104.9 | 127.1 |
| 50–59 | 9.1 | 29.6 | 30.8 | 214.2 | 249.5 |
| 60 + | 10.5 | 81.6 | 87.4 | 539.7 | 584.0 |
| All | 2.4 | 12.3 | 14.8 | 100.2 | 114.4 |

a Rate per 100,000 population for the given time period. Aboriginal and Torres Strait Islander population data is based on the Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) as at 2021.


## Severity

(NNDSS, FluCAN, SPRINT-SARI)

To provide a more accurate assessment of severity (defined as those admitted to ICU and/or died), cases with an illness onset in the last two weeks of the reporting period have been excluded from the analyses given the delay between illness onset and development of severe illness.

Since the emergence of the Omicron variant, the number of cases with severe illness peaked in mid-January 2022, at over 1,250 severe cases per week (data not shown). Since this time there has been a consistent decrease in the number of cases developing severe illness, with a smaller peak observed with each subsequent Omicron wave. Please note, this is likely due to a combination of factors such as high COVID-19 vaccination coverage, hybrid immunity and access to oral antiviral treatments that have led to a reduction in the overall societal impact of the pandemic, marked by fewer severe cases over time. Since the end of the fifth Omicron wave, the weekly number of cases with severe illness decreased to 45 in the week ending 27 August 2023, followed by a gradual increase from early September, signalling the start of the sixth Omicron wave (Figure 3).

Figure 3: **COVID-19 cases, deaths and ICU admissions, Australia, by date of onset, Australia,   
24 October 2022 – 19 November 2023** a,b



a Source: NNDSS, extracted on 22 November 2023 for cases with an illness onset from 24 October 2022 to 19 November 2023.

b Shaded bars at the right represent the most recent two reporting weeks and should be interpreted with caution, as cases with an illness onset in these weeks may not have yet developed severe disease.

Similar to previous transmission waves, rates of severe illness during the Omicron waves remain highest in older age groups, particularly those aged 60 years and older (Figure 4). Throughout the fifth Omicron wave (1 March – 13 August 2023), the highest rate of severe illness among those aged 60 years and older was observed in the week ending 28 May 2023 at 5.1 cases per 100,000 population. The rate of severe illness in this age group has increased slightly since the start of the sixth Omicron wave and subsequently stabilised from early-October 2023 onwards. In comparison, rates of severe illness in younger age groups have remained relatively low and stable throughout earlier Omicron waves, not surpassing 1.2 cases per 100,000 population per week since the start of the fourth Omicron wave (Figure 4).

Figure 4: **Age-specific weekly rates of COVID-19 cases admitted to ICU or died, by date of onset, Australia, 24 October 2022 to 5 November 2023** a,b

A line graph encompassing the fourth and fifth Omicron waves and the sixth Omicron wave  to date, showing the rates per 100,000 population per week of ICU admission or death, by age group (0–9; 10–19; 20–29; 30–39; 40–49; 50–59; and 60+ years of age). Rates of ICU admission and death have been consistently higher, across this time period, in those aged 60 years and older than in other age groups. The severe-illness peak for the fourth Omicron wave, in those aged 60 years and older, occurred on the week ending 18 December 2022 with approximately 7.5 cases per 100,000 population per week; the corresponding fifth Omicron wave peak in this age group, on the week ending 28 May 2023, amounted to approximately 5.0 severe-illness cases per 100,000 population per week. Following the fifth-wave peak, severe-illness cases among the 60+ years age group have fluctuated around approximately 1.0–1.2 cases per 100,000 per week from early July until the end of the current reporting period. 
Throughout the time period covered by this figure, incidence of severe illness in age groups under 60 years old has been substantially lower, with the 50–59 years age group recording a peak of approximately 0.9 severe-illness cases per 100,000 population per week for the fourth Omicron wave, on the week ending 25 December 2022, with a poorly defined fifth-wave peak of approximately 0.6 severe-illness cases per 100,000 population per week in the weeks ending 14 May 2023 and 11 June 2023. The severe-illness case rates for those below 50 years of age have remained at or below 0.5 such cases per 100,000 population per week throughout the time period covered by this figure.

a Source: NNDSS, extracted on 22 November 2023 for cases with an illness onset from 24 October 2022 to 5 November 2023; cases with an illness onset in the last two weeks (6–19 November 2023) were excluded to account for the delay between onset and development of severe illness.


b Population data based on Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) as at June 2022.

### Hospitalisation and ICU admissions

Influenza Complications Alert Network—FluCAN

Between 13 December 2021 and 19 November 2023, there were 18,208 hospital admissions with confirmed COVID-19 reported at Influenza Complications Alert Network (FluCAN) sentinel sites, including 5.7% (1,034/18,208) admitted directly to ICU (Figure 5). During the latest four-week reporting period (23 October – 19 November 2023), there were 277 hospital admissions with COVID-19 reported at FluCAN sentinel sites, with 9.0% (25/277) admitted directly to ICU. The proportion of COVID-19 ICU admissions in the year to date (1 January to 19 November 2023) was 5.9% (263/4,421). This was equal to the proportion for the same period in 2022.

Figure 5: **Weekly trends for patients admitted with confirmed COVID-19 to FluCAN sentinel hospitals, Australia, 13 December 2021 – 19 November 2023** a



a Source: FluCAN.4

Short Period Incidence Study of Severe Acute Respiratory Infection—SPRINT-SARI

Between 15 December 2021 and 19 November 2023, there were 6,391 COVID-19 cases admitted to ICUs participating in the sentinel surveillance system, Short Period Incidence Study of Severe Acute Respiratory Infection (SPRINT-SARI)5 (Table 5). Most patients (62.3%; 3,980/6,391) were discharged home; 12.8% (821/6,391) died in ICU and 5.1% (329/6,391) died within the general hospital ward, with an overall in-hospital mortality rate of 18.0% (1,150/6,391).

In the four-week reporting period (25 September – 19 November 2023), there were 95 adult patients with COVID-19 (57 males, 38 females; median age: 64 years; interquartile range [IQR]: 49.5–74.0 years) admitted to ICU reported at SPRINT-SARI sentinel sites (Table 5).

Table 5: **Patient outcomes for adult COVID-19 cases (aged greater than or equal to 18 years), Australia, 15 December 2021 – 19 November 2023** a

|  |  |  |
| --- | --- | --- |
| Outcomes | Reporting period 23 October – 19 November 2023 (n = 95) | Omicron wave to date 15 December 2021 – 19 November 2023 (n = 6,391) |
| **Patient status** |  |  |
| Ongoing care in ICU | 33 (34.7%) | 47 (0.7%) |
| Ongoing care in hospital ward b | 23 (24.2%) | 55 (0.9%) |
| Transfer to other hospital/facility | 0 (0%) | 448 (7.0%) |
| Transfer to rehabilitation | 0 (0%) | 612 (9.6%) |
| Discharged home | 32 (33.7%) | 3,980 (62.3%) |
| Mortality – ICU | 7 (7.4%) | 821 (12.8%) |
| Mortality – hospital ward | 0 (0%) | 329 (5.1%) |
| Unknown | 0 (0%) | 73 (1.1%) |
| Missing c | 0 (0%) | 26 (0.4%) |

a Source: SPRINT-SARI.5

b Patients who were admitted in ICU/hospital wards with no discharge information for less than 90 days were assumed to have ongoing care in the hospital.

c Patients who were admitted to ICU/hospital wards for more than 90 days with no discharge information were treated as ‘missing data’.


Since the start of the Omicron wave (15 December 2021) to 19 November 2023, for patients admitted to SPRINT-SARI sentinel sites with COVID-19 (n = 6,391), the median length of stay in ICU was 3.4 days (IQR: 1.7–7.1 days); the median length of stay in hospital was 11.0 days (IQR: 6.0–20.0 days); and the median duration of mechanical ventilation was 4.1 days (IQR: 1.5–9.3 days).

During the four-week reporting period (23 October – 19 November 2023), for adult patients admitted to SPRINT-SARI sentinel sites with COVID-19 (n = 95), the median length of stay in ICU was 2.9 days (IQR: 2.2–5.3 days); the median length of stay in hospital was 7.7 days (IQR: 5.2–11.0 days); and the median duration of mechanical ventilation was 1.9 days (IQR: 0.7–5.1 days).

### Risk factors for severe disease

Comorbidity data extracted from SPRINT-SARI reflect the sickest patients with COVID-19 who are managed in ICU; data are therefore not generalisable to all cases. Figure 6 shows the most prevalent comorbidities among adult patients admitted to ICU with COVID-19 during the four-week period 23 October – 19 November 2023, where comorbidity information was available. Of those adult patients admitted to ICU during the four-week reporting period, for whom comorbidity data was known, 38.9% of adult ICU patients (37/95) had three or more comorbidities.

**Figure 6: Prevalence of comorbidities for COVID-19 cases among admitted adult ICU patients   
(aged greater than or equal to 18 years), Australia, 23 October – 19 November 2023** a,b



a Source: SPRINT-SARI. Only includes adult cases (≥ 18 years old) and excludes those with missing data on comorbidities or where comorbidity is unknown.


b Abbreviated comorbidities defined as: Cardiac: chronic cardiac disease; Pulmonary: chronic pulmonary disease (not including asthma); Immune: chronic immunosuppression; ACEi/ARB: past use of ACE inhibitor or A2 Blocker; CKD: chronic kidney disease and Rheumato: rheumatologic disorder.

### Paediatric Inflammatory Multisystem Syndrome – Temporally Associated with SARS-CoV-2

Paediatric Active Enhanced Disease Surveillance

Since the start of the pandemic to 19 November 2023, there have been 186 cases of paediatric inflammatory multisystem syndrome – temporally associated with SARS-CoV-2 (PIMS-TS) reported to the Paediatric Active Enhanced Disease Surveillance network (PAEDS), with no new cases reported in the last four weeks, and a total of 20 cases reported since the start of 2023 (Figure 7). The majority of PIMS-TS cases to date have occurred in those aged 5 to < 12 years (53%; 98/186), followed by those aged 6 months to < 5 years (27%; 51/186). To date, there have been no PIMS-TS associated deaths.

Figure 7: **PIMS-TS cases reported to PAEDS, by sample month and level of care required, Australia,   
1 June 2021 – 19 November 2023** a



a Source: PAEDS.

### COVID-19 deaths

Since the beginning of the pandemic to 19 November 2023, there have been 23,640 COVID-19-associated deaths reported to the NNDSS, with 646 COVID-19-associated deaths notified in the current Omicron wave (Table 6). The overall crude case fatality rate from the start of the Omicron wave to date is 0.19%, which is lower than the crude case fatality rate for the Delta wave (0.71%) (Table 7).

Table 6: **Deaths associated with COVID-19 by reporting period, Australia, 1 January 2020 –   
19 November 2023** a,b,c

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Jurisdiction c | Sixth Omicron wave to date 14 August –  19 November 2023 | Fifth Omicron wave  1 March –  13 August 2023 | Fourth Omicron wave 24 October 2022 – 28 February 2023 | Omicron wave to date 15 December 2021 – 19 November 2023 | Pandemic to date 1 January 2020 –  19 November 2023 |
| ACT | 7 (1.1%) | 46 (1.5%) | 38 (1.0%) | 267 (1.2%) | 282 (1.2%) |
| NSW | 189 (29.3%) | 1,078 (34.3%) | 1,065 (29.0%) | 7,134 (33.4%) | 7,834 (33.1%) |
| NT | 4 (0.6%) | 14 (0.4%) | 18 (0.5%) | 114 (0.5%) | 115 (0.5%) |
| Qld | 59 (9.1%) | 519 (16.5%) | 510 (13.9%) | 3,398 (15.9%) | 3,405 (14.4%) |
| SA | 2 (0.3%) | 238 (7.6%) | 321 (8.8%) | 1,669 (7.8%) | 1,674 (7.1%) |
| Tas. | 17 (2.6%) | 54 (1.7%) | 63 (1.7%) | 308 (1.4%) | 322 (1.4%) |
| Vic. | 347 (53.7%) | 971 (30.9%) | 1,355 (36.9%) | 7,182 (33.6%) | 8,704 (36.8%) |
| WA | 21 (3.3%) | 225 (7.2%) | 298 (8.1%) | 1,295 (6.1%) | 1,304 (5.5%) |
| **Australia** | 646 (100.0%) | 3,145 (100.0%) | 3,668 (100.0%) | 21,367 (100.0%) | 23,640 (100.0%) |

a Source: NNDSS, extracted on 22 November 2023 for deaths with an illness onset date to 19 November 2023.

b Deaths are categorised into time periods using date of death. Deaths with a missing date of death are classified using date of illness onset.

c ACT: Australian Capital Territory; NSW: New South Wales; NT: Northern Territory; Qld: Queensland; SA: South Australia; Tas.: Tasmania; Vic.: Victoria; WA: Western Australia.

Table 7: **COVID-19 associated case fatality rates among cases notified to NNDSS, by age group and date of onset, 1 January 2020 to 5 November 2023** a,b,c,d

|  |  |  |  |
| --- | --- | --- | --- |
| Age group (years) | Omicron wave to date 15 December 2021 – 5 November 2023 | Delta wave 16 June – 14 December 2021 | Pandemic to date 1 January 2020 – 5 November 2023 |
| 0–9 | < 0.05% | < 0.05% | < 0.05% |
| 10–19 | < 0.05% | < 0.05% | < 0.05% |
| 20–29 | < 0.05% | < 0.05% | < 0.05% |
| 30–39 | < 0.05% | 0.06% | < 0.05% |
| 40–49 | < 0.05% | 0.18% | < 0.05% |
| 50–59 | < 0.05% | 0.65% | 0.06% |
| 60 + | 1.10% | 6.13% | 1.20% |
| Unknown | 0.00% | 0.00% | 0.00% |
| Australia | 0.19% | 0.71% | 0.20% |

a Source: NNDSS, extracted on 22 November 2023 for deaths with an illness onset date to 5 November 2023.

b To account for the lag between illness onset and the development of severe illness, cases with an onset date in the last two weeks have been excluded from calculations of the case fatality rate.

c A value of 0.00% indicates that no COVID-19 associated fatalities occurred during the indicated period for the specified age group.

d Crude case fatality rates which reflect number of deaths as a proportion of reported COVID-19 cases during specific periods. Note, the current crude case fatality rates are likely overestimated due to changes in case ascertainment and increased underreporting of non-severe cases.

## Genomic surveillance and virology

(Communicable Disease Genomics Network, AusTrakka and jurisdictional sequencing laboratories)

### Variants of concern (VOC)

AusTrakka6 is actively monitoring and reporting on one lineage and its associated sub- and sub-sub-lineages, currently designated as a variant of concern (VOC) by international organisations, including the World Health Organization (WHO): Omicron (B.1.1.529). The Omicron variant displays a characteristic set of mutations which differentiate the lineage from previously circulating VOCs. Further information on variants and their mutations is available in the Technical Supplement.2

There have been five major sub-lineages defined under B.1.1.529: BA.1, BA.2, BA.3, BA.4 and BA.5, and a large number of sub-lineages, including recombinants, under these; all are designated Omicron. Unlike previous periods in Australia’s COVID-19 waves, where one or two dominant lineages were the main driver of disease, there is currently significant diversity in the range of sub-sub-lineages circulating within Australia. During this reporting period, more than 200 unique lineages have been identified, and it is likely that there are more that are not being characterised through whole genome sequencing. This diversity of circulating lineages has sometimes been referred to as a ‘variant soup’. Many of these circulating lineages will die out without causing a significant disease burden, but others appear to have stronger growth potential.

### Variants of interest and variants under monitoring

The Communicable Diseases Genomics Network (CDGN) VOC working group tracks notable SARS-CoV-2 variants, including:

* three variants of interest (VOI): XBB.1.5, XBB.1.16, and EG.5; and
* the following variants under monitoring (VUMs) and their descendent lineages: BA.2.75 and BA.2.75.2 (including CH\*), BQ.1 and BQ.1.1\*, and recombinants XBB\* (in particular XBB.1.9.1\* and XBB.1.9.2\*), and XBF\*.

This report uses the variants of interest (VOI) classification for lineages with possible evidence for epidemiological, pathological or immunological features of concern. This is consistent with CDGN usage and with the WHO use of the term.7,8 Variants under monitoring (VUM) are other lineages with early observations of potential significance, but little to no evidence of current concern. In this report, details are included of Omicron subvariants under monitoring as designated by the WHO.

### AusTrakka SARS-CoV-2 genomic epidemiology

From 23 October to 19 November 2023, there were 1,109 sequences uploaded to AusTrakka, with the most recent collection date of 13 November 2023. This represents a 35% increase in the number of sequences compared to the previous reporting period. Almost all sequences uploaded during this reporting period have been assigned to sub-lineages within B.1.1.529 (Omicron) or to recombinants consisting of one or more Omicron sub-lineages.

Of the 1,109 sequences uploaded to AusTrakka between 23 October and 19 November 2023:

* 90.8% (1,007/1,109) were recombinant or recombinant sub-lineages; and
* 9.2% (102/1,109) were BA.2 sub-sub-lineages.

No BA.1, BA.3, BA.4 or BA.5 Omicron sub-lineages were identified.

From 1 July 2023, jurisdictional sequencing strategies for SARS-CoV-2 have changed. Some jurisdictions have ceased SARS-CoV-2 sequencing, while other jurisdictions have reduced the number of SARS-CoV-2 cases being sequenced. For jurisdictions which are continuing SARS-CoV-2 genomic surveillance, SARS-CoV-2 cases which are likely to be prioritised for sequencing include ICU or hospitalised cases, high-risk cases, or cases of clinical significance. As a result, these changes are likely to affect the representativeness of the distribution of SARS-CoV-2 sub-lineages across Australia.

Case numbers and sequencing proportion are primarily based on polymerase chain reaction (PCR) results only, as RATs do not allow for sequencing. Since late 2022, the rates of PCR for testing and subsequent referrals of positive PCR samples to sequencing laboratories have decreased significantly, resulting in changes to sequencing strategies across the country.

The Australian SARS-CoV-2 genome sequences in AusTrakka identified as VOCs, VOIs or VUMs are highlighted in Table 8. The VOIs and VUMs where the proportion has increased compared to the previous reporting period are highlighted in orange, those that have remained stable are highlighted in blue, while those where proportions have decreased are highlighted in green.

In the reporting period to 19 November 2023, the VOI EG.5 (XBB.1.9.2.5) made up more than half of all sequences, with 58.4% of all samples uploaded. The increase in EG.5, a sub-lineage of XBB.1.9.2, is the main contributor to the increase in sequences grouped within XBB.1.9.1, XBB.1.9.2, and sub-lineages (Table 8). The other VOI XBB sublineages, XBB.1.16 and XBB.1.5, now make up only a small proportion of sequences, and decreased slightly during this reporting period (Table 8). The VUM XBB.2.3 continues to drop, down to 2.7% of sequences in the four-week reporting period to 19 November, from 7.2% in the preceding four-week period ending 22 October. An additional 78 BA.2.86 sequences were seen this reporting period, but this newly designated VUM has not seen the substantial increase that early international reports suggested, and still only represents 7.0% of lineages for the reporting period. One newly designated WHO VUM has been added to this report. DV.7 (CH.1.1.1) is a sub-lineage of BA.2.75/CH.1.1, and has been observed 82 times in AusTrakka to-date, including 19 sequences notified in this reporting period (Table 8).

Figure 8: **Omicron sub-lineage in Australia since 1 January 2023 by sample collection date, showing (A) proportions and (B) count per week** a,b,c

Figure 8A plots the proportions of SARS-CoV-2 sequences recorded, by lineage and by date of specimen collection, for each collection week from 1 January 2023 by sample collection date. The figure shows that the dominant sub-lineages sequenced in January–February 2023 were BA.2.75 and the XBF recombinant lineage, with smaller proportions of BA.5, XBB.1.5 and XBC at this time. In subsequent months, the XBF proportion has diminished steadily while that of BA.2.75 has ebbed more gradually, with the largest proportions of sequenced Omicron subvariants identified as XBB.1.5 (March 2023), XBB.1.9.1 (April¬–May 2023), and XBC (June–July 2023). In recent weeks, the largest proportion have been identified as the recently assigned VOI EG.5.

Figure 8B shows the weekly numbers of SARS-CoV-2 sequences, by lineage and by date of specimen collection, for each collection week from 1 January 2023 by sample collection date. Sequence numbers dropped substantially across June and July, before largely plateauing across August and rising somewhat through September and October. In the current four-week reporting period (23 October – 19 November 2023), the majority of sequences reported are from the first fortnight (23 October – 5 November) and the preceding weeks, with EG.5 consistently dominant in recent weeks.

a Sequences in AusTrakka aggregated by epidemiological week.

b The dashed box indicates the distribution of sequences collected within the reporting period.

c Proportions in Figure 8A may not be representative when sequence numbers are small; refer to Figure 8B. Data for earlier epidemiological weeks may change between reporting periods as sequences with older collection dates are uploaded. These numbers are not equivalent to number of cases, as there are many cases which may not be sequenced. Non-VOI and non-VUM Omicron sub-lineages have been collapsed into parent lineages BA.1, BA.2, BA.3, BA.4 and BA.5.

Table 8: **Australian SARS-CoV-2 genome sequences in AusTrakka, identified as variants of concern, variants of interest or variants under monitoring and proportion of positive cases sequenced for the current and previous reporting periods, and since 23 January 2020** a,b,c

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variant category | Measure | Reporting period 23 October – 19 November 2023 | Previous reporting period 25 September – 22 October 2023 | Total sequences to date 23 January 2020 – 19 November 2023 |
| **Variants of concern (VOC)** | BA.1 | 0 (0%) | 0 (0%) | 26,272 (16.0%) |
| BA.2 (excluding BA.2.75) | 78 (7.0%) | 8 (0.97%) | 41,649 (25.4%) |
| BA.2.75 | 24 (2.2%) | 15 (1.8%) | 14,482 (8.8%) |
| BA.3 | 0 (0%) | 0 (0%) | 3 (<0.1%) |
| BA.4 | 0 (0%) | 0 (0%) | 5,052 (3.0%) |
| BA.5 | 0 (0%) | 0 (0%) | 43,203 (26.3%) |
| Total recombinants | 1,007 (90.8%) | 801 (97.2%) | 33,165 (20.2%) |
| **Total VOC** | **1,109 (100%)** | **824 (100%)** | **163,826 (100%)** |
| **Variants of interest (VOI)** | XBB.1.5 + sub-lineages | 5 (0.45%) | 63 (7.6%) | 5,391 (3.3%) |
| XBB.1.16 | 69 (6.2%) | 120 (14.6%) | 4,448 (2.7%) |
| EG.5 (XBB.1.9.2.5) | 648 (58.4%) | 382 (46.4%) | 2,734 (1.7%) |
| **Variants under monitoring (VUM)** | XBB + all sub-lineages | 847 (76.4%) | 704 (85.4%) | 21,335 (13.0%) |
| XBB.1.9.1, XBB.1.9.2 + sub-lineages | 727 (65.5%) | 446 (54.1%) | 8,017 (5.1%) |
| XBB.2.3 | 30 (2.7%) | 39 (4.7%) | 1,341 (0.82%) |
| XBF | 0 (0%) | 0 (0%) | 6,535 (4.0%) |
| XBC | 41 (3.7%) | 95 (11.5%) | 4,325 (2.6%) |
| BA.2.86 | 78 (7.0%) | 8 (0.97%) | 104 (0.06%) |
| DV.7 (CH.1.1.1) | 19 (1.7%) | — | 82 (0.05%) |
| **Omicron BA.2** | BA.2.75 + sub-lineages | 24 (2.2%) | 15 (1.8%) | 14,482 (8.8%) |
| CH.1.1 + sub-lineages (BA.2.75.1.1) | 24 (2.2%) | 15 (1.8%) | 4,396 (2.7%) |

a All lineages have been designated as variants of concern (VOC), variants of interest (VUI) or variants under monitoring (VUM) in Australia, by the CDGN VOC working group.

b Sequencing of samples from cases identified in the reporting period may be in process at the time of reporting. Remaining unsequenced samples may be due to jurisdictional sequencing strategy, or where samples have been deemed unsuitable for sequencing (typically because viral loads were too low for sequencing to be successful).

c Proportional changes compared to the previous 28-day period are highlighted by the following colours: green boxes indicate a decrease; orange boxes indicate an increase and blue boxes indicate no change/stable.


## Acute respiratory illness

(FluTracking, ASPREN)

Based on self-reported FluTracking data,9 there has been an overall decrease in the incidence of ‘fever and cough’ symptoms since the peak in early June 2023 at 2.4%. In the current four-week reporting period, week-on-week increases were observed, with the average proportion of ‘fever and cough’ symptoms now similar to the proportion observed during the same period in 2022, at 1.4% (Figure 9).


The incidence of ‘runny nose and sore throat’ symptoms has slowly decreased since the peak in the week ending 28 May 2023 (1.9%) with two subsequent smaller increases observed in the week ending 2 July 2023 (1.7%) and 20 August 2023 (1.6%). In the current four-week reporting period, the average proportion of ‘runny nose and sore throat’ symptoms was 1.3%, which is similar to the proportion observed during the same period in 2022 (Figure 10).

Figure 9: **Weekly trends in fever and cough amongst FluTracking survey participants (age-standardised) compared to the average of the previous five years, Australia, 1 January 2020 – 19 November 2023** a



a In years prior to 2020, FluTracking was activated during the main Influenza season from May to October. A historical average beyond the week ending 11 October is therefore not available. In 2020, FluTracking commenced ten weeks early to capture data for COVID-19.

Figure 10: **Weekly trends in runny nose and sore throat symptoms amongst FluTracking survey participants (age-standardised), Australia, 29 March 2020 – 19 November 2023** a



a Data on runny nose and sore throat were only collected systematically after 29 March 2020, therefore a historical average for this symptom profile is unavailable.

Over the reporting period, FluTracking data indicated that 10.0% of participants with ‘fever and cough’ were tested for SARS-CoV-2 with a PCR test and 79.4% were tested using a RAT (noting that in some instances RATs will be followed up by a PCR test for the same case). Of those with ‘runny nose and sore throat’, 3.3% were tested for SARS-CoV-2 using a PCR test and 56.2% were tested using a RAT. In the current reporting period, the percent positivity for ‘fever and cough’ symptoms increased for both PCR (23.0%) and RAT (47.8%) compared to the previous reporting period. For ‘runny nose and sore throat’ symptoms, the percent positivity also increased for both PCR (11.9%) and RAT (9.6%). Note that participants with one set of symptoms are not excluded from having the other. It is important to acknowledge that there may be legitimate reasons why people did not get tested, including barriers to accessing testing. Symptoms reported to FluTracking are not specific to COVID-19 and may also be due to infections with other respiratory pathogens and to chronic diseases, such as asthma.

Since the start of 2023 to 19 November 2023, of those presenting to sentinel ASPREN sites with influenza-like illness who were tested for respiratory viruses, 62.5% (1,000/1,599) tested positive for a respiratory virus. Among those positive, the most common viruses detected were rhinovirus (33.5%; 335/1,000) followed by influenza A (19.2%; 192/1,000), influenza B (12.3%; 123/1,000), SARS-CoV-2 (10.3%; 103/1,000), and respiratory syncytial virus (9.5%; 95/1,000).

## COVID-19 trends by WHO region

As of 19 November 2023, over 772 million COVID-19 cases and over six million deaths have been reported globally since the start of the pandemic, with a global case fatality rate (CFR) of approximately 0.90%.10 Current trends in reported COVID-19 cases are an underestimate of the true number of global infections due to the reduction in testing and reporting in many countries. For more information, please refer to the WHO monthly COVID-19 epidemiological update.11

# Acknowledgements

We thank public health staff from incident emergency operations centres and public health units in state and territory health departments, and the Australian Government Department of Health and Aged Care, along with state and territory public health laboratories. We thank those who have provided data from surveillance systems, such as ASPREN, FluTracking, FluCAN, PAEDS, SPRINT-SARI, the Communicable Disease Genomics Network, AusTrakka and jurisdictional sequencing laboratories.

# Author details

Corresponding author

Viral Respiratory Diseases Epidemiology and Surveillance Section

Interim Australian Centre for Disease Control, Australian Government Department of Health and Aged Care  
GPO Box 9484, MDP 14,  
Canberra, ACT 2601.

Email: respiratory.surveillance@health.gov.au

# References

1. COVID-19 National Incident Room Surveillance Team. COVID-19 Australia: Epidemiology Report 80: Reporting period ending 22 October 2023. Commun Dis Intell (2018). 2024;48. doi:  https://doi.org/10.33321/cdi.2024.48.3.
2. COVID-19 National Incident Room Surveillance Team. Technical supplement. COVID-19 Australia: Epidemiology reporting. Commun Dis Intell (2018). 2021;45. doi:  https://doi.org/10.33321/cdi.2021.45.2.
3. Australian Government Department of Health and Aged Care. Coronavirus (COVID-19) – CDNA National Guidelines for Public Health Units. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 14 October 2022. [Accessed on 9 November 2022.] Available from: https://www.health.gov.au/resources/publications/coronavirus-covid-19-cdna-national-guidelines-for-public-health-units.
4. FluCAN (The Influenza Complications Alert Network). FluCAN (Influenza surveillance). [Webpage.] Melbourne: Monash Health, FluCAN. [Accessed on 30 June 2023.] Available from: https://monashhealth.org/services/monash-infectious-diseases/research/influenza-research/flucan-influenza-surveillance-2/.
5. Australian and New Zealand Intensive Care Research Centre (ANZIC-RC). SPRINT-SARI: Short period incidence study of severe acute respiratory infection. [Internet.] Melbourne: Monash University, ANZIC-RC; 2020. Available from: https://www.monash.edu/medicine/sphpm/anzicrc/research/sprint-sari.
6. Communicable Diseases Genomics Network (CDGN). AusTrakka. [Website.] Melbourne: CDGN; 2020. Available from: https://www.cdgn.org.au/austrakka.
7. World Health Organization (WHO). Updated working definitions and primary actions for SARS-CoV-2 variants. Geneva: WHO; 15 March 2023. [Accessed on 11 October 2023.] Available from: https://www.who.int/publications/m/item/updated-working-definitions-and-primary-actions-for--sars-cov-2-variants.
8. WHO. Tracking SARS-CoV-2 variants. [Webpage.] Geneva: WHO; 17 August 2023. [Accessed on 23 August 2023.] Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants.
9. Dalton C, Durrheim D, Fejsa J, Francis L, Carlson S, d’Espaignet ET et al. Flutracking: a weekly Australian community online survey of influenza-like illness in 2006, 2007 and 2008*.* Commun Dis Intell Q Rep. 2009;33(3):316–22.
10. WHO. COVID-19 epidemiological update – 24 November 2023. [Internet.] Geneva: WHO;   
    24 November 2023. [Accessed on 8 December 2023.] Available from: https://www.who.int/publications/m/item/covid-19-epidemiological-update---24-november-2023.
11. WHO. Coronavirus disease (COVID-19) Weekly Epidemiological Updates and Monthly Operational Updates. [Webpage.] Geneva: WHO; 2024. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.

# Appendix A: Supplementary figures and tables

Table A.1: **COVID-19 cases and rates per 100,000 population, by age group, sex, and date of onset, Australia, 15 December 2021 – 19 November 2023** a,b,c,d

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Four-week reporting period | | | | | | Omicron wave to date | | | | | | |
|  | 23 October – 19 November 2023 | | | | | | 15 December 2021 – 19 November 2023 | | | | | | |
| **Age group (years)** | Cases | | | Rate per 100,000 population | | | Cases | | | Rate per 100,000 population | | | |
| Male | Female | People**d** | Male | Female | People**d** | Male | Female | People**d** | Male | Female | Peopled |  |
| 0–9 | 1,632 | 1,413 | 3,048 | 101.7 | 93.2 | 97.7 | 526,843 | 500,209 | 1,147,820 | 32,823.0 | 32,994.6 | 36,775.7 |  |
| 10–19 | 1,129 | 1,160 | 2,299 | 69.2 | 75.4 | 72.5 | 661,736 | 702,933 | 1,501,216 | 40,543.9 | 45,673.7 | 47,339.4 |  |
| 20–29 | 1,155 | 2,256 | 3,426 | 65.6 | 133.7 | 99.3 | 801,412 | 981,775 | 1,908,971 | 45,501.3 | 58,181.6 | 55,352.9 |  |
| 30–39 | 1,669 | 2,990 | 4,672 | 88.7 | 155.9 | 123.0 | 826,935 | 1,034,921 | 2,008,927 | 43,950.7 | 53,966.1 | 52,877.2 |  |
| 40–49 | 1,598 | 2,843 | 4,446 | 97.3 | 169.1 | 133.8 | 686,418 | 872,125 | 1,680,209 | 41,783.2 | 51,880.9 | 50,550.5 |  |
| 50–59 | 1,712 | 2,898 | 4,612 | 109.2 | 179.0 | 144.7 | 557,535 | 693,779 | 1,339,291 | 35,562.8 | 42,851.0 | 42,026.3 |  |
| 60–69 | 1,930 | 2,585 | 4,516 | 142.7 | 179.3 | 161.6 | 405,610 | 470,717 | 930,048 | 29,979.5 | 32,650.9 | 33,279.9 |  |
| 70–79 | 2,277 | 2,519 | 4,801 | 234.6 | 240.4 | 237.9 | 261,129 | 266,581 | 552,659 | 26,909.8 | 25,443.5 | 27,384.8 |  |
| 80–89 | 2,003 | 2,494 | 4,502 | 497.7 | 500.7 | 499.9 | 119,793 | 136,132 | 265,461 | 29,766.2 | 27,329.9 | 29,477.6 |  |
| 90 + | 756 | 1,393 | 2,153 | 996.9 | 1,002.8 | 1,002.6 | 31,583 | 58,638 | 92,962 | 41,646.4 | 42,213.6 | 43,289.7 |  |

a Source: NNDSS, extracted on 22 November 2023 for notifications to 19 November 2023.

b Population data based on Australian Bureau of Statistics (ABS) Estimated Resident Population (ERP) as at June 2022.

c Excludes cases where age was unknown.

d Total cases includes those where sex was unknown and those classified as X, i.e., persons who reported their sex as another term, other than male or female.

Communicable Diseases Intelligence

Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Health Protection Policy & Surveillance Division, Department of Health and Aged Care. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.

© 2024 Commonwealth of Australia as represented by the Department of Health and Aged Care

ISSN: 2209-6051 Online

This journal is indexed by Index Medicus and Medline.

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (CC BY-NC-ND) available from https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**

The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at www.pmc.gov.au/resources/commonwealth-coat-arms-information-and-guidelines);
* any logos (including the Department of Health and Aged Care’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**

Opinions expressed in *Communicable Diseases Intelligence* are those of the authors and not necessarily those of the Australian Government Department of Health and Aged Care or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**

Enquiries regarding any other use of this publication should be addressed to the CDI Editor at: cdi.editor@health.gov.au

**Communicable Diseases Network Australia**

Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia. www.health.gov.au/cdna

**Editor**: Christina Bareja • **Deputy Editor**: Simon Petrie • **Design and Production**: Lisa Thompson

**Editorial Advisory Board**: David Durrheim, Mark Ferson, Clare Huppatz, John Kaldor, Martyn Kirk, Meru Sheel and Steph Williams

**Contacts**

CDI is produced by:

Health Protection Policy & Surveillance Division, Australian Government Department of Health and Aged Care,  
GPO Box 9848, (MDP 6) CANBERRA ACT 2601

Website: www.health.gov.au/cdi

Email: cdi.editor@health.gov.au

**Submit an Article**

You are invited to submit your next communicable disease related article to the *Communicable Diseases Intelligence* (CDI) for consideration. More information regarding CDI can be found at: www.health.gov.au/cdi.

Further enquiries should be directed to: cdi.editor@health.gov.au.